Safety and quality in paediatric procedural sedation: what really matters?

Abstract

Purpose of reviewThis review gives an overview of the safety aspects for paediatric procedural sedation and a discussion of possibilities for optimizing structure, processes and outcomes.Recent findingsProcedural sedation in paediatric patients is performed by providers of different specialties and compliance with safety standards is a basic requirement regardless of provider specialty. This includes preprocedural evaluation, monitoring, equipment and profound expertise of sedation teams. The choice of sedative medications and the possibility of incorporating nonpharmacological methods play an important role for optimal outcome. In addition, an ideal outcome from the patient's perspective includes optimized processes and clear and empathetic communication.SummaryInstitutions providing paediatric procedural sedation must ensure the comprehensive training of sedations teams. Furthermore, institutional standards for equipment, processes and optimal choice of medication depending on performed procedure and comorbidities of the patient must be established. At the same time, organizational and communication aspects should be considered.

Design and User Experience of VirNE Application: Deep Breathing Exercise in a Virtual Natural Environment to Reduce Treatment Anxiety in Pediatrics

“…The treatment may include sedative medications, with Midazolam, propofol, or dexmedetomidine being the most common choices. However, it's important to note that the use of sedatives poses a risk of adverse effects for the patient [15].…”

Effects of Using Guided Deep Breathing Exercises in a Virtual Natural Environment to Reduce Stress during Pediatric Treatment

“…The fear of an upcoming procedure or needles has been treated by distraction or educating the patient about the upcoming situation [10]. The treatment may include sedative medication-most commonly Midazolam, propofol, or dexmedetomidine-but the use of sedative medications places the patient at risk of adverse effects [11].…”